Product Information
INSULIN LISPRO JR 100 UNIT/ML KWIKPEN is a generic product labeled by Eli Lilly and Company, priced at $10.1994 per ML under NDC 00002775205. Its NADAC has been published 298 times since Jan 20, 2021.
Strength
100 [iU]/mL
Manufacturer
Eli Lilly and CompanyNDC
00002775205
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
INSULIN LISPROApproval Type
Biologic (BLA)
FDA Application
BLA020563On Market Since
2/12/2020
Pharmacological Classes
Price Statistics
The NADAC for INSULIN LISPRO JR 100 UNIT/ML KWIKPEN has been published 298 times since Jan 20, 2021, and over the history we have for it it has declined 40.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $10.1994 per ML |
|---|---|
| All-time high | $17.1088 (Oct 13, 2021) |
| All-time low | $10.1187 (Jan 18, 2023) |
| 52-week high | $10.2081 |
| 52-week low | $10.1845 |
| Median price | $10.2025 |
| Average price | $11.3695 |
| Largest weekly change | -40.0% (Jan 12, 2022) |
| Weeks tracked | 298 |
| Tracking since | Jan 20, 2021 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 76% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Eli Lilly and Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Insulin lispro market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Insulin Analog class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of INSULIN LISPRO JR 100 UNIT/ML KWIKPEN?
The current National Average Drug Acquisition Cost (NADAC) for INSULIN LISPRO JR 100 UNIT/ML KWIKPEN, manufactured by Eli Lilly and Company, is $10.1994 per ML (NDC 00002775205), effective Sep 30, 2026.
How has the price of INSULIN LISPRO JR 100 UNIT/ML KWIKPEN changed over time?
Over the history we have for it, the NADAC for INSULIN LISPRO JR 100 UNIT/ML KWIKPEN has declined 40.4%. It has been tracked across 298 weekly CMS publications since Jan 20, 2021.
What are the highest and lowest recorded NADAC prices for INSULIN LISPRO JR 100 UNIT/ML KWIKPEN?
Since Jan 20, 2021, the NADAC for INSULIN LISPRO JR 100 UNIT/ML KWIKPEN has ranged from a low of $10.1187 (Jan 18, 2023) to a high of $17.1088 (Oct 13, 2021), with a median of $10.2025 per ML.
Are there cheaper alternatives to INSULIN LISPRO JR 100 UNIT/ML KWIKPEN?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, INSULIN LISPRO 100 UNIT/ML VL, is $2.4026 per ML — about 76% below INSULIN LISPRO JR 100 UNIT/ML KWIKPEN.
Who manufactures INSULIN LISPRO JR 100 UNIT/ML KWIKPEN?
INSULIN LISPRO JR 100 UNIT/ML KWIKPEN (NDC 00002775205) is labeled by Eli Lilly and Company, and CMS classifies it as a generic product.